SARS-CoV-2 in coronary blood from thrombus aspiration in a patient with myocardial infarction.

Coron Artery Dis

Department of Critical Care, INSERM, FHU SEPSIS, RHU RECORDS, Université de Versailles Saint-Quentin-en-Yvelines, Université de Paris Saclay, Laboratory Infection and Inflammation, U1173, AP-HP, Raymond Poincaré Hospital, Versailles, France.

Published: June 2022

Download full-text PDF

Source
http://dx.doi.org/10.1097/MCA.0000000000001107DOI Listing

Publication Analysis

Top Keywords

sars-cov-2 coronary
4
coronary blood
4
blood thrombus
4
thrombus aspiration
4
aspiration patient
4
patient myocardial
4
myocardial infarction
4
sars-cov-2
1
blood
1
thrombus
1

Similar Publications

Some of the millions of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have developed new sequelae after recovering from the initial disease, termed post-acute sequelae of coronavirus disease 2019 (PASC). One symptom is anxiety, which is likely due to three etiologies: brain structural changes, neuroendocrine disruption, and neurotransmitter alterations. This review provides an overview of the current literature on the pathophysiological pathways linking coronavirus disease 2019 to anxiety, as well as the possible mechanisms of action in which an increasingly scrutinized treatment method, enhanced external counter-pulsation (EECP), is able to alleviate anxiety.

View Article and Find Full Text PDF

Pre-infection anticoagulant exposure and SARS-CoV-2 infection outcomes - Differential mortality by age.

Thromb Res

January 2025

Department of Hematology, Hadassah University Medical Center, Jerusalem, Israel; Braun School of Public Health and Community Medicine, Hadassah Medical Organization, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Background: The risk of thrombosis increases after SARS-CoV-2 infection. This study aimed to assess associations between pre-infection anticoagulant exposure and SARS-CoV-2 infection-related outcomes in a population-based cohort.

Methods: Members of the "Meuhedet" health maintenance organization aged >45 years who tested positive for SARS-CoV-2 infection (03/2020-04/2022) were followed.

View Article and Find Full Text PDF

Mitochondria and the Repurposing of Diabetes Drugs for Off-Label Health Benefits.

Int J Mol Sci

January 2025

Department of Microbiology & Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore.

This review describes our current understanding of the role of the mitochondria in the repurposing of the anti-diabetes drugs metformin, gliclazide, GLP-1 receptor agonists, and SGLT2 inhibitors for additional clinical benefits regarding unhealthy aging, long COVID, mental neurogenerative disorders, and obesity. Metformin, the most prominent of these diabetes drugs, has been called the "Drug of Miracles and Wonders," as clinical trials have found it to be beneficial for human patients suffering from these maladies. To promote viral replication in all infected human cells, SARS-CoV-2 stimulates the infected liver cells to produce glucose and to export it into the blood stream, which can cause diabetes in long COVID patients, and metformin, which reduces the levels of glucose in the blood, was shown to cut the incidence rate of long COVID in half for all patients recovering from SARS-CoV-2.

View Article and Find Full Text PDF

Coronavirus disease 2019 (COVID-19) poses significant risks for solid organ transplant recipients, who have atypical but poorly characterized immune responses to infection. We aim to understand the host immunologic and microbial features of COVID-19 in transplant recipients by leveraging a prospective multicenter cohort of 86 transplant recipients age- and sex-matched with 172 non-transplant controls. We find that transplant recipients have higher nasal SARS-CoV-2 viral abundance and impaired viral clearance, and lower anti-spike IgG levels.

View Article and Find Full Text PDF

The COVID-19 pandemic exposed a global deficiency of systematic, data-driven guidance to identify high-risk individuals. Here, we illustrate the utility of routinely recorded medical history to predict the risk for 1741 diseases across clinical specialties and support the rapid response to emerging health threats such as COVID-19. We developed a neural network to learn from health records of 502,489 UK Biobank participants.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!